How much is Oral Genome worth in 2026?

Oral Genome has a current valuation of N/A based on their Accelerator/Incubator round and secondary market data.

How much funding has Oral Genome raised?

Oral Genome has raised N/A in total funding across 1 funding rounds.

Oral Genome

Diagnostic Equipment

Oral Genome valuation and funding history | Last updated: September 8, 2022 | 1 funding rounds

Current Valuation

N/A

As of September 8, 2022

Total Funding Raised

N/A

Across 1 round

Last Round

Accelerator/Incubator

Amount undisclosed

Last Funding

Sep 2022

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
September 8, 2022	Accelerator/Incubator	Undisclosed	N/A	-

Valuation Analysis

Current Valuation Metrics

Oral Genome is currently valued at N/A as of September 8, 2022.

Track Oral Genome Valuation Updates

Get notified when Oral Genome raises new funding or valuation changes

Explore More Data

Detailed analysis for Oral Genome

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Oral Genome's valuation history, funding rounds, and growth metrics.

No credit card required

What is Oral Genome Worth in 2026?

Oral Genome is a leading private company in the Diagnostic Equipment sector. Track Oral Genome's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Oral Genome Valuation is Determined

Private company valuations like Oral Genome's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.